[1]JELLINGER K A. Prevalence of cerebrovascular lesions in Parkinson’s disease[J]. Acta Neuropathol,2003,105(5):415-419.
[2]VAN DER HOLST H M,VAN UDEN I W,TULADHAR A M,et al. Cerebral small vessel disease and incident parkinsonism:the RUN DMC study[J]. Neurology,2015,85(18):1569-1577.
[3]GLASS P G,LEES A J,BACELLAR A,et al. The clinical features of pathologically confirmed vascular parkinsonism[J]. J Neurol Neurosurg Psychiatry,2012,83(10):1027-1029.
[4]中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国血管性帕金森综合征诊断与治疗专家共识[J]. 中华神经科杂志. 2017,50(5):326-331. Parkinson’s Disease & Movement Disorders
Society,Chinese Society of Neurology,Parkinson’s Disease & Movement Disorders Society,Chinese Neurology Association . Chinese experts’consensus of diagnosis and treatment of vascular parkinsonism[J]. Chin J Neurol,2017,50(5):326-331.
[5]FITZGERALD P M,JANKOVIC J. Lower body parkinsonism:evidence for vascular etiology[J]. Mov Disord,1989,4(3):249-260.
[6]ZIJLMANS J C,DANIEL S E,HUGHES A J,et al. Clinicopathological investigation of vascular parkinsonism,including clinical criteria for diagnosis[J]. Mov Disord,2004,19(6):630-640.
[7]KORCZYN A D. Vascular parkinsonism--characteristics,pathogenesis and treatment[J]. Nat Rev Neurol,2015,11(6):319-326.
[8]COLOSIMO C,MORGANTE L,ANTONINI A,et al. Non-motor symptoms in atypical and secondary parkinsonism:the PRIAMO study[J]. J Neurol,2010,257(1):5-14.
[9]罗倩,彭思佳,王笑瑗,等. 血管性帕金森综合征的临床特征及神经影像学研究进展[J]. 中国卒中杂志,2021,16(9):967-970. LUO Q,PENG S J,WANG X Y,et al. Progress of clinical and neuroimaging features of vascular parkinsonism[J]. Chin J Stroke,2021,16(9):967-970.
[10]NARASIMHAN M,SCHWARTZ R,HALLIDAY G. Parkinsonism and cerebrovascular disease[J/OL]. J Neurol Sci,2022,433:120011[2023-02-20]. https://doi.org/10.1016/j.jns.2021.120011.
[11]CHOI S M,KIM B C,NAM T S,et al. Midbrain atrophy in vascular Parkinsonism[J]. Eur Neurol,2011,65(5):296-301.
[12]WANG H C,HSU J L,LEEMANS A. Diffusion tensor imaging of vascular parkinsonism:structural changes in cerebral white matter and the association with clinical severity[J]. Arch Neurol,2012,69(10):1340-1348.
[13]SALSONE M,CALIGIURI M E,VESCIO V,et al. Microstructural changes of normal-appearing white matter in vascular Parkinsonism[J/OL]. Parkinsonism Relat Disord,2019,63:60-65[2023-02-20]. https://doi.org/10.1016/j.parkreldis.2019.02.046.
[14]LEE Y H,LEE S,CHUNG S J,et al. The pattern of FP-CIT PET in pure white matter hyperintensities-related vascular parkinsonism[J/OL]. Parkinsonism Relat Disord,2021,82:1-6[2023-02-15]. https://doi.org/10.1016/j.parkreldis.2020.11.002.
[15]ZHAO X J,NIU X Y,YOU H Y,et al. Signal alteration of substantia nigra on 3. 0T susceptibility-weighted imaging in Parkinson’s disease and vascular parkinsonism[J]. Curr Med Sci,2019,39(5):831-835.
[16]MATSUURA K,II Y,MAEDA M,et al. Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia[J/OL]. Parkinsonism Relat Disord,2021,87:75-81[2023-02-15]. https://doi.org/10.1016/j.parkreldis.2021.05.002.
[17]CHEN Y F,TSENG Y L,LAN M Y,et al. The relationship of leukoaraiosis and the clinical severity of vascular parkinsonism[J]. J Neurol Sci,2014,346(1/2):255-259.
[18]DUNET V,DEVERDUN J,CHARROUD C,et al. MRI volumetric morphometry in vascular parkinsonism[J]. J Neurol,2017,264(7):1511-1519.
[19]ZIJLMANS J,EVANS A,FONTES F,et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease[J]. Mov Disord,2007,22(9):1278-1285.
[20]NAVARRO-OTANO J,GAIG C,MUXI A,et al. 123I-MIBG cardiac uptake,smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson’s disease[J]. Parkinsonism Relat Disord. 2014,20(2):192-197.
[21]HORVATH J,BURKHARD P R,BOURAS C,et al. Etiologies of parkinsonism in a century-long autopsy-based cohort[J]. Brain Pathol,2013,23(1):28-33.
[22]REKTOR I,BOHNEN N I,KORCZYN A D,et al. An updated diagnostic approach to subtype definition of vascular parkinsonism-recommendations from an expert working group[J/OL]. Parkinsonism Relat Disord,2018,49:9-16[2023-03-10]. https://doi.org/10.1016/j.parkreldis.2017.12.030.
[23]LING M J,AGGARWAL A,MORRIS J G. Dopa-responsive parkinsonism secondary to right temporal lobe haemorrhage[J]. Mov Disord,2002,17(2):402-404.
[24]MIGUEL-PUGA A,VILLAFUERTE G,SALAS-PACHECO J,et al. Therapeutic interventions for vascular parkinsonism:a systematic review and meta-analysis[J/OL]. Front Neurol,2017,8:481[2023-02-10]. https://doi.org/10.3389/fneur.2017.00481.
[25]YIP C W,CHEONG P W,GREEN A,et al. A prospective pilot study of repetitive transcranial magnetic stimulation for gait dysfunction in vascular parkinsonism[J]. Clin Neurol Neurosurg. 2013,115(7):887-891.
[26]MAKSIMOVICH I V. Intracerebral transcatheter laser photobiomodulation therapy in the treatment of Binswanger’s disease and vascular parkinsonism:research and clinical experience[J]. Photobiomodul Photomed Laser Surg,2019,37(10):606-614.